|
1
|
PDQ Adult Treatment Editorial Board:
Non-small cell lung cancer treatment (PDQ®Patient
version. NCI. 2002–2015 May 12.
|
|
2
|
Evans TL: Chemotherapy in advanced
non-small cell lung cancer: Optimal treatment approach for elderly
and patients with poor performance status. Lung cancer. Am J Hemat
Oncol. 7:12–16. 2015.
|
|
3
|
Du Y, Su T, Zhao L, Tan X, Chang W, Zhang
H and Cao G: Associations of polymorphisms in DNA repair genes and
MDR1 gene with chemotherapy response and survival of non-small cell
lung cancer. PLoS One. 9:e998432014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen WL, Kuo KT, Chou TY, Chen CL, Wang
CH, Wei YH and Wang LS: The role of cytochrome c oxidase subunit Va
in non-small cell lung carcinoma cells: Association with migration,
invasion and prediction of distant metastasis. BMC Cancer.
12:2732012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McKeage K: Docetaxel: A review of its use
for the first-line treatment of advanced castration-resistant
prostate cancer. Drugs. 72:1559–1577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lyseng-Williamson KA and Fenton C:
Docetaxel: A review of its use in metastatic breast cancer. Drugs.
65:2513–2531. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bayet-Robert M, Morvan D, Chollet P and
Barthomeuf C: Pharmacometabolomics of docetaxel-treated human MCF7
breast cancer cells provides evidence of varying cellular responses
at high and low doses. Breast Cancer Res Treat. 120:613–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niu L, Deng J, Zhu F, Zhou N, Tian K, Yuan
H and Lou H: Anti-inflammatory effect of Marchantin M contributes
to sensitization of prostate cancer cells to docetaxel. Cancer
Lett. 348:126–134. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim E, Matsuse M, Saenko V, Suzuki K,
Ohtsuru A, Mitsutake N and Yamashita S: Imatinib enhances
docetaxel-induced apoptosis through inhibition of nuclear factor-κB
activation in anaplastic thyroid carcinoma cells. Thyroid.
22:717–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu H, Xin Y, Zhao J, Sun D, Li W, Hu Y and
Wang S: Metronomic docetaxel chemotherapy inhibits angiogenesis and
tumor growth in a gastric cancer model. Cancer Chemother Pharmacol.
68:879–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Hu YL and Cheng YY: Docetaxel
influences autocrine of transforming growth factors and induces
apoptosis in human ovarian cancer cell line AO. Chin Med Sci J.
21:2042006.PubMed/NCBI
|
|
12
|
He X, Li C, Wu X and Yang G: Docetaxel
inhibits the proliferation of non-small-cell lung cancer cells via
upregulation of microRNA-7 expression. Int J Clin Exp Pathol.
8:9072–9080. 2015.PubMed/NCBI
|
|
13
|
Indo K, Hoshikawa H, Kamitori K, Yamaguchi
F, Mori T, Tokuda M and Mori N: Effects of D-allose in combination
with docetaxel in human head and neck cancer cells. Int J Oncol.
45:2044–2050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
http://www.cancer.gov/cancertopics/druginfo/fda-docetaxelNational
Cancer Institute. Last Updated. 3:282014.
|
|
15
|
Huang CY, Beer TM, Higano CS, True LD,
Vessella R, Lange PH, Garzotto M and Nelson PS: Molecular
alterations in prostate carcinomas that associate with in vivo
exposure to chemotherapy: Identification of a cytoprotective
mechanism involving growth differentiation factor 15. Clin Cancer
Res. 13:5825–5833. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Marzo AM, Platz EA, Sutcliffe S, Xu J,
Gronberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG:
Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7:256–269.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seruga B, Zhang H, Bernstein LJ and
Tannock IF: Cytokines and their relationship to the symptoms and
outcome of cancer. Nat Rev Cancer. 8:887–899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiba T, Marusawa H and Ushijima T:
Inflammation-associated cancer development in digestive organs:
Mechanisms and roles for genetic and epigenetic modulation.
Gastroenterology. 143:550–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawanishi S, Ohnishi S, Ma N, Hiraku Y and
Murata M: Crosstalk between DNA damage and inflammation in the
multiple steps of carcinogenesis. Int J Mol Sci. 18:18082017.
View Article : Google Scholar
|
|
20
|
Ding N, Maiuri AR and O'Hagan HM: The
emerging role of epigenetic modifiers in repair of DNA damage
associated with chronic inflammatory diseases. Mutation
Research-Reviews in Mutation Research: Online September 28, 2017.
In Press.
|
|
21
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sica A, Wang JM, Colotta F, Dejana S,
Mantovani A, Oppenheim JJ, Larsen CG, Zachariae CO and Matsushima
K: Monocyte chemotactic and activating factor gene expression
induced in endothelial cells by IL-1 and tumor necrosis factor. J
Immunol. 144:3034–3038. 1990.PubMed/NCBI
|
|
24
|
Carr MW, Roth SJ, Luther E, Rose SS and
Springer TA: Monocyte chemoattractant protein 1 acts as a
T-lymphocyte chemoattractant. Proc Natl Acad Sci USA. 91:3652–3656.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu LL, Warren MK, Rose WL, Gong W and Wang
JM: Human recombinant monocyte chemotactic protein and other C-C
chemokines bind and induce directional migration of dendritic cells
in vitro. J Leukoc Biol. 60:365–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barcelos LS, Talvani A, Teixeira AS,
Cassali GD, Andrade SP and Teixeira MM: Production and in vivo
effects of chemokines CXCL1-3/KC and CCL2/JE in a model of
inflammatory angiogenesis in mice. Inflamm Res. 53:576–584. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Lu Y and Pienta KJ: Multiple
roles of chemokine (C-C motif) ligand 2 in promoting prostate
cancer growth. J Natl Cancer Inst. 102:522–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ajuebor MN, Swain MG and Perretti M:
Chemokines as novel therapeutic targets in inflammatory diseases.
Biochem Pharmacol. 63:1191–1196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Said N, Sanchez-Carbayo M, Smith SC and
Theodorescu D: RhoGDI2 suppresses lung metastasis in mice by
reducing tumor versican expression and macrophage infiltration. J
Clin Invest. 122:1503–1518. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abangan RS Jr, Williams CR, Mehrotra M,
Duncan JD and Larue AC: MCP1 directs trafficking of hematopoietic
stem cell-derived fibroblast precursors in solid tumor. Am J
Pathol. 176:1914–1926. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qian DZ, Rademacher BL, Pittsenbarger J,
Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS and Beer TM:
CCL2 is induced by chemotherapy and protects prostate cancer cells
from docetaxel-inducedcytotoxicity. Prostate. 70:433–442.
2010.PubMed/NCBI
|
|
33
|
Kirk PS, Koreckij T, Nguyen HM, Brown LG,
Snyder LA, Vessella RL and Corey E: Inhibition of CCL2 signaling in
combination with docetaxel treatment has profound inhibitory
effects on prostate cancer growth in bone. Int J Mol Sci.
14:10483–10496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fridlender ZG, Buchlis G, Kapoor V, Cheng
G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA and
Albelda SM: CCL2 blockade augments cancer immunotherapy. Cancer
Res. 70:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fridlender ZG, Kapoor V, Buchlis G, Cheng
G, Sun J, Wang LC, Singhal S, Snyder LA and Albelda SM: Monocyte
chemoattractant protein-1 blockade inhibits lung cancer tumor
growth by altering macrophage phenotype and activating CD8+ cells.
Am J Respir Cell Mol Biol. 44:230–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qian DZ, Wei YF, Wang X, Kato Y, Cheng L
and Pili R: Antitumor activity of the histone deacetylase inhibitor
MS-275 in prostate cancer models. Prostate. 67:1182–1193. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Annovazzi L, Mellai M, Caldera V, Valente
G, Tessitore L and Schiffer D: mTOR, S6 and AKT expression
inrelation to proliferation and apoptosis/autophagy in glioma.
Anticancer Res. 29:3087–3094. 2009.PubMed/NCBI
|
|
39
|
Falasca M: PI3K/Akt signaling pathway
specific inhibitors: A novel strategy to sensitize cancer cells to
anti-cancer drugs. Curr Pharm Des. 16:1410–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mabuchi S, Ohmichi M, Kimura A, Hisamoto
K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E,
Nakatsuji Y, et al: Inhibition of phosphorylation of BAD and Raf-1
by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol
Chem. 277:33490–33500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo
J and Rosen N: The BAD protein integrates survival signaling by
EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor
cells. Cancer Cell. 8:287–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Basu A and Haldar S: Microtubule-damaging
drugs triggered bcl2 phosphorylation-requirement of phosphorylation
on both serine-70 and serine-87 residues of bcl2 protein. Int J
Oncol. 13:659–664. 1998.PubMed/NCBI
|
|
46
|
Haldar S, Basu A and Croce CM: Serine-70
is one of the critical sites for drug-induced Bcl2 phosphorylation
in cancer cells. Cancer Res. 58:1609–1615. 1998.PubMed/NCBI
|
|
47
|
Wang TH, Wang HS, Ichijo H, Giannakakou P,
Foster JS, Fojo T and Wimalasena J: Microtubuleinterfering agents
activate c-Jun N-terminal kinase/stress-activated protein kinase
through both Ras and apoptosis signal-regulating kinase pathways. J
Biol Chem. 273:4928–4936. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yamamoto K, Ichijo H and Korsmeyer SJ:
BCL-2 is phosphorylated and inactivated by an ASK1/Jun nterminal
protein kinase pathway normally activated at G(2)/M. Mol Cell Biol.
19:8469–8478. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tang XR and Amar S: p53 suppresses
CCL2-induced subcutaneous tumor xenograft. Tumour Biol.
36:2801–2808. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Egunsola AT, Zawislak CL, Akuffo AA,
Chalmers SA, Ewer JC, Vail CM, Lombardo JC, Perez DN and Kurt RA:
Growth, metastasis, and expression of CCL2 and CCL5 by murine
mammary carcinomas are dependent upon Myd88. Cell Immunol.
272:220–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu T, Miao Z, Jiang J, Yuan S, Fang W, Li
B and Chen Y: Visfatin mediates SCLC cells migration across brain
endothelial cells through upregulation of CCL2. Int J Mol Sci.
16:11439–11451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu FY, Fan J, Tang L, Zhao YM and Zhou CC:
Atypical chemokine receptor D6 inhibits human non-small cell lung
cancer growth by sequestration of chemokines. Oncol Lett. 6:91–95.
2013. View Article : Google Scholar : PubMed/NCBI
|
